98%
921
2 minutes
20
Glycated albumin (GA) is one of the proteins that replaces several sugar moieties and can be used as an indicator of diabetes mellitus. We developed a sensing system that uses GA in the early detection of diabetes mellitus. In this study, HYC acetylated (Ac-) at the N-terminals of the peptide was combined with wheat germ agglutinin (WGA) to recognize glucose moieties. The Ac-HYC-WGA was constructed as a GA-sensing probe. The tyrosine residues of YC exhibited an oxidation peak, and His-tag moieties were introduced to separate Ac-HYC-WGA in the synthesis of the probe. The Ac-HYC-WGA probe binds with the 1-2 molecules of Ac-HYC per WGA using matrix assisted laser desorption/ionization-time of flight (MALDI-TOF)-MS. Next, the functions of Ac-HYC-WGA were evaluated using voltammetry. The number of electron-transfers was calculated based on the relationship between the peak potential and logarithm of scan rate and was 3.03. In the electrochemical measurements with mannose and bovine serum albumin, the peak currents were similar to that of GA alone. By contrast, a decrease in the peak current was suppressed when glucose was added to the solution containing the probe. As a result, Ac-HYC-WGA was selectively bound to the glucose moieties of GA. The calibration curve via differential pulse voltammetry was proportional to the concentrations of GA and ranged from 1.0 × 10 to 2.0 × 10 M with a detection limit of 3.3 × 10 M.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1248/cpb.c23-00702 | DOI Listing |
PLoS One
September 2025
Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
There is a lack of longitudinal data on type 2 diabetes (T2D) in low- and middle-income countries. We leveraged the electronic health records (EHR) system of a publicly funded academic institution to establish a retrospective cohort with longitudinal data to facilitate benchmarking, surveillance, and resource planning of a multi-ethnic T2D population in Malaysia. This cohort included 15,702 adults aged ≥ 18 years with T2D who received outpatient care (January 2002-December 2020) from Universiti Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.
View Article and Find Full Text PDFEndocrine
September 2025
Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Front Immunol
September 2025
Department of Rheumatology and Immunology, The First Hospital of China Medical University, China Medical University, Shenyang, Liaoning, China.
CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requirements-have attracted increasing attention. This article presents a complex case of a patient with SLE combined with APS and TBIRS.
View Article and Find Full Text PDFEur J Clin Pharmacol
September 2025
Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai, India.
Background: The prevalence of diabetes mellitus has surged fourfold globally over the past 30Â years, creating a major health concern. Imeglimin, a novel oral antidiabetic agent, has shown promising results in the management of type 2 diabetes mellitus (T2DM).
Objectives: This systematic review aimed to evaluate the efficacy and safety of imeglimin in patients with T2DM based on available clinical studies.
J Diabetes Sci Technol
September 2025
Guy's and St Thomas NHS Foundation Trust, Guy's Hospital, London, UK.
Aim: This review aims to map the existing literature on the use of diabetes technology in people receiving dialysis, with a focus on utilization, accuracy, and effectiveness.
Methods: A scoping review was conducted using the Joanna Briggs Institute methodology, with systematic searches of Medline, Embase, and CINAHL for studies on diabetes technologies in dialysis populations.
Results: The search identified 1060 continuous glucose monitoring (CGM) and 1467 continuous subcutaneous insulin infusion or automated insulin delivery (CSII/AID) records, with 64 studies included.